Statins did not reduce colorectal cancer in WHI analysis

November 8, 2010

The use of statins among a group of postmenopausal women did not reduce the risk for colorectal cancer, according to the results of a prospective analysis of data from the large population-based Women's Health Initiative (WHI).

"The results of our study are consistent with the majority of the literature suggesting no significant reduction in colorectal cancer risk among users of ," said Michael S. Simon, M.D., professor of oncology in the department of oncology at Wayne State University and Barbara Ann Karmanos Cancer Institute, Detroit.

Simon presented these study results at the Ninth Annual AACR Frontiers in Cancer Prevention Research Conference, held here from Nov. 7-10, 2010.

According to Simon, the results from several case-control studies have shown a moderate reduction in colorectal cancer risk in people who use statins. However, a majority of the literature researching the association, including data from and cohort studies, show no association between statin use and reduced colorectal cancer risk.

"Colorectal cancer is the third leading cause of and death in the United States," he said. "While regular screening has been shown to be effective in decreasing mortality, the majority of the population receives no screening, or inadequate screening, which supports the need to focus on chemoprevention to lower death rates."

One method of colorectal cancer chemoprevention being researched is the use of statins. In this study, Simon and colleagues used data from the WHI to determine if there was a link between colorectal cancer prevention and statins. The study included 159,219 aged 50 to 79 years. There were 2,000 cases of colorectal cancer identified during an average of 10 years of follow-up.

Women participating in the study were asked to bring all medications to their screening interviews and the use of any statin, or other lipid-lowering medication, was entered into the WHI database. About 8 percent of women in the study were using statins.

The yearly rate of colorectal cancer did not differ between women taking statins and those not taking statins. There was also no difference in risk for colorectal cancer based on the duration of statin use, type of statin, statin potency or use of other lipid-lowering medications. In addition, the researchers identified no link between statin use and tumor location, stage, grade or histology.

According to Simon though, the effect of statins on colorectal risk deserves some additional study in certain patient populations.

"A recent study suggested a possible greater effect of statins in reducing both cardiovascular and colorectal among individuals with a genetic variation of the enzyme inhibited by statins," he said. "This finding suggests that future studies should focus on individuals at high risk based on family history or genetic predisposition."

Related Stories

Recommended for you

CAR-T immunotherapy may help blood cancer patients who don't respond to standard treatments

October 20, 2017
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers. Newly approved ...

Researchers pinpoint causes for spike in breast cancer genetic testing

October 20, 2017
A sharp rise in the number of women seeking BRCA genetic testing to evaluate their risk of developing breast cancer was driven by multiple factors, including celebrity endorsement, according to researchers at the University ...

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.